Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
HOWL

HOWL - Werewolf Therapeutics, Inc. Stock Price, Fair Value and News

$0.79-0.04 (-4.82%)
Market Closed

62/100

HOWL

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

62/100

HOWL

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

HOWL Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

HOWL Price Action

Last 7 days

25.4%

Last 30 days

17.9%

Last 90 days

-28.2%

Trailing 12 Months

-34.7%

HOWL RSI Chart

HOWL Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

HOWL Valuation

Market Cap

38.3M

Price/Earnings (Trailing)

-0.53

Price/Sales (Trailing)

7.61

Price/Free Cashflow

-0.6

HOWL Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

HOWL Fundamentals

HOWL Revenue

Revenue (TTM)

7.8M

HOWL Earnings

Earnings (TTM)

-72.8M

Earnings Growth (Yr)

1.82%

Earnings Growth (Qtr)

8.96%

HOWL Profitability

Return on Equity

-245.97%

Return on Assets

-91.48%

Free Cashflow Yield

-165.97%

HOWL Investor Care

Shares Dilution (1Y)

8.92%

Diluted EPS (TTM)

-1.59

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202419.2M15.9M7.8M0
202320.9M24.8M25.8M0
20224.2M8.3M12.3M16.4M
202177.3K91.5K105.8K120.0K
202000063.0K
Get all data in R, Python etc through our Historical Stock Data APIs

About Werewolf Therapeutics, Inc.

HOWL
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an IL-21 INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.
 CEO
 WEBSITEhttps://werewolftx.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES48

Werewolf Therapeutics, Inc. Frequently Asked Questions

HOWL is the stock ticker symbol of Werewolf Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Mar 13 2026, market cap of Werewolf Therapeutics, Inc. is 38.35 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Mar 13 2026, HOWL's PE ratio (Price to Earnings) is -0.53 and Price to Sales (PS) ratio is 7.61. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. HOWL PE ratio will change depending on the future growth rate expectations of investors.